Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood samples, Skin biopsies.
- Who it may be relevant to
- Registry conditions: Vitiligo, Psoriasis, Alopecia Areata, Atopic Dermatitis. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders
Detailed description
This study was a single-center prospective study to collect blood and skin tissue at the time of consultation with a patient with non-segmental vitiligo, psoriasis, atopic dermatitis or alopecia areata, in order to better understand and compare blood and skin immune response in chronic inflammatory skin disorders: psoriasis, alopecia areata, atopic dermatitis and vitiligo.
Interventions
- Biological Blood samples
Blood samples: serum and PBMC - Biological Skin biopsies
These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
Primary outcome measures
- Description of the phenotype and function of blood and skin T-cell in chronic inflammatory skin disorders: psoriasis, vitiligo, atopic dermatitis, alopecia areata [Time frame: Day 1]
Eligibility criteria
Inclusion criteria
- Patients aged 18 to 75 years;
- Patients with non-segmental vitiligo;
- Patients with plaque psoriasis;
- Patients with atopic dermatitis;
- Patients with alopecia areata sclerosis;
- written consent, free, informed and signed by the patient and the investigator (before any examination required by the study);
- Subject affiliated or beneficiary of a social security system.
Exclusion criteria
- Patients with segmental vitiligo
- Patients under local treatment (topical corticosteroid-Calcineurin inhibitor) for less than two weeks.
- Patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine, Apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, dupilumab) for less than 4 weeks.
- Pregnant or breastfeeding women
- Patient (e) under guardianship
- Patient (e) Non-affiliated (e) a social protection
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Service de Dermatologie - Hôpital Saint-André — Bordeaux
Publications
- Jacquemin C, Taieb A, Boniface K, Seneschal J; FHU ACRONIM. Imbalance of peripheral follicular helper T lymphocyte subsets in active vitiligo. Pigment Cell Melanoma Res. 2019 Jul;32(4):588-592. doi: 10.1111/pcmr.12763. Epub 2019 Feb 15. PMID 30552832
Identifiers
NCT: NCT03976622 · CHUBX 2017/55